Address: Bull. ‘Tsar Liberator’ 2 , 1000 Sofia, Bulgaria
Tel: +359 2 921 57 00
Servier, founded in 1954, is the first independent pharmaceutical group. We are present in 140 countries, with more than 20 000 employees, including close to 3000 in R&D.
Servier is established in 140 countries with its main therapeutic products used to treat diabetes, cardiovascular diseases, CNS disorders, oncology and rheumatological diseases.
After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on…
The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC),…
Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of…
Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing…
One of NNE Pharmaplan’s latest exciting news is that last year you established offices to accommodate your existing customers in Belgium. What were the strategic motivations for establishing a presence…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your…
With an expenditure of more than 10% of GDP on health, Belgium maintains one of the world’s leading healthcare systems. That said, could you please comment on the current state…
Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
See our Cookie Privacy Policy Here
